ETHK Labs Inc. (the “Company”) has announced the appointment of Ms. Yi Xiao as an executive director and chief scientist, effective February 6, 2026. Her term will last until the Company’s annual general meeting in 2026, at which point she will be eligible for re-election.

Ms. Yi, aged 32, obtained a Bachelor of Medicine degree in clinical medicine from the University of South China in June 2016 and a Doctor of Medicine degree in obstetrics and gynaecology from Southern Medical University in June 2022. Since July 2022, she has served as a professor at the Translational Medicine Centre of Zhujiang Hospital of Southern Medical University and, in 2023, as a part-time young researcher of the Greater Bay Area Institute of Precision Medicine (Guangzhou). Ms. Yi has led multiple research projects and secured approvals for related medical products, with several of her academic papers appearing in international journals.

Under the service agreement, Ms. Yi will receive a monthly director’s remuneration of HK$30,000, along with potential discretionary bonuses and other benefits. The remuneration was recommended by the remuneration committee and approved by the board of directors with reference to her duties and market practice.